Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Chalcis – page 13

159 clinical trials in Chalcis, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Chalcis at a glance
159
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

159 trials in Chalcis

Open in trial search

Study on the Effectiveness and Safety of Oral Semaglutide Compared to Placebo in Children and Adolescents with Type 2 Diabetes Using Metformin or Basal Insulin

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study on the Effectiveness and Safety of Tiragolumab, Atezolizumab, and Drug Combination for Patients with Urothelial Carcinoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study of MK-7684A with Chemoradiotherapy Compared to Chemoradiotherapy with Durvalumab for Patients with Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus+2

Not recruiting

Study of LY3502970 for Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gilead Sciences Inc.

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Sepsis

Not recruiting

Study on Avibactam and Drug Combination for Treating Severe Infections in Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Anidulafungin
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Chalcis

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Chalkida is focused entirely on cardiovascular diseases, with studies centered on different forms of heart failure. The research is mainly aimed at evaluating new treatment approaches that may help reduce serious heart-related events and improve symptom control.

  • Heart failure with reduced ejection fraction
  • HFpEF and HFmrEF linked to obesity
  • Heart failure with systemic inflammation
  • Testing whether new therapies can improve outcomes beyond standard care

These trials are exploring both treatment effectiveness and the potential to lower risks such as cardiovascular death, hospitalisation, and urgent care visits.

02 Heart Failure Research

Current studies in this area are examining whether targeted therapies can better manage symptomatic heart failure in patients whose condition remains difficult to control. The focus is on improving long-term outcomes for people with more advanced forms of the disease.

  • HFrEF with severely reduced ejection fraction
  • Comparing a new treatment with placebo
  • Assessing added benefit alongside guideline-directed medical therapy

This line of research aims to clarify whether new options can offer meaningful benefit in everyday clinical care.

03 Inflammation and Obesity in Heart Failure

Another important research theme links heart failure with systemic inflammation and obesity, reflecting growing interest in how these factors influence disease progression. The studies are designed to test whether newer therapies can address these overlapping risks more effectively.

  • HFpEF and HFmrEF with obesity
  • Heart failure with inflammation
  • Evaluating whether treatment can reduce major cardiovascular events
  • Supporting better control of complex, mixed-risk patient groups

Together, these trials reflect a focused effort in Greece to improve care for people living with challenging forms of heart failure.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.